|Send to printer »|
GEN News Highlights : Mar 28, 2013
Flipping the Genetic Switch
Researchers have shed new light on how genes turn on and off. Working with placentas, the team from UC Davis and the University of British Columbia discovered that 37% of the placental genome has regions of lower methylation, called partially methylated domains (PMDs), in which gene expression is turned off. This differs from most human tissues, in which 70% of the genome is highly methylated.
While PMDs have been identified in cell lines, this is the first time they have been found in regular human tissue. The team says that in addition to enhancing our understanding of epigenetics, this work could influence cancer research and help illuminate how environmental toxins affect fetal development.
“I like to think of epigenetics as a layer on top of your genetic code,” says senior author Janine LaSalle, Ph.D., professor of medical microbiology and immunology at UC Davis. “It’s not the DNA sequence but the layers on top of that—and methylation is the first layer.” In methylation, a group of carbon and hydrogen atoms (a methyl group) attaches to DNA, adjusting how genes are expressed. “Those layers provide a lot of information to the cells on where and when to turn on the genes,” she says.
How and when genes are activated—or inactivated—can have a profound impact on human development, cancer, and the biological legacy of environmental toxins. Prior to this research, PMDs had only been found in cultured cell lines, which led some scientists to wonder if they existed outside the test tube. This study confirms they exist in placental tissue, a critically important window into fetal development.
“The placenta is the interface between mother and fetus,” notes Dr. LaSalle. “It’s a time capsule from when a lot of important methylation events occurred.”
She says that placental tissue was interesting to study because it has a number of invasive characteristics often associated with cancer. A number of cancers, such as breast and colon, have widespread PMDs. Dr. LaSalle notes that anticancer epigenetic therapies that adjust methylation could be refined based on this improved understanding of PMDs.
This work could also enhance our ability to detect genetic defects, she explains. Methylation and other epigenetic data provides information that cannot be found in the genome alone. For example, the vast majority of cells in the body contain identical genetic code. However, the added information provided by methylation allows scientists to determine where specific DNA came from.
“Methylation patterns are like fingerprints, showing which tissue that DNA is derived from,” says Dr. LaSalle. “You can’t get that information from just the DNA sequence. As a result, methylation studies could be a very rich source for biomarkers.”
In the study, PMDs encompassed 37% of the placental genome, including 3,815 genes—around 17% of all genes. When found in low-methylation regions, these genes were less likely to be transcribed into proteins. Researchers also found that PMDs also contain more highly methylated CpG islands (genomic areas with large numbers of cytosine-guanine pairs), which are often associated with gene transcriptional silencing of promoters.
Because the placental PMDs contained many genes associated with neuronal development, and specifically autism, Dr. LaSalle notes that future research could investigate how epigenetics impacts autism genes at birth.
“We are looking for biomarkers that predict neurodevelopmental outcomes,” Dr. LaSalle says. “Now we have a series of snapshots from a critical period where we think environmental factors are playing a role in the developing brain.”
The paper was published online this week in the Proceedings of the National Academy of Sciences (PNAS). The article is titled “The human placenta methylome”.
© 2013 Genetic Engineering & Biotechnology News, All Rights Reserved